Homologous recombination deficiency in ovarian cancer

a review of its epidemiology and management

Authors

  • Renata Rodrigues da Cunha Colombo onadi Universidade de Sao Paulo. Faculdade de Medicina. Hospital das Clinicas. Instituto do Cancer do Estado de Sao Paulo
  • Rodrigo Nogueira Fogace Universidade de Sao Paulo. Faculdade de Medicina. Hospital das Clinicas. Instituto do Cancer do Estado de Sao Paulo
  • Vanessa Costa Miranda Universidade de Sao Paulo. Faculdade de Medicina. Hospital das Clinicas. Instituto do Cancer do Estado de Sao Paulo
  • Maria del Pilar Estevez Diz Universidade de Sao Paulo. Faculdade de Medicina. Hospital das Clinicas. Instituto do Cancer do Estado de Sao Paulo

DOI:

https://doi.org/10.6061/clinics/2018/e450s

Keywords:

Ovarian Cancer, Homologous Recombination Deficiency, PARP Inhibitors, BRCA Mutation

Abstract

Ovarian cancer patients with homologous recombination deficiencies exhibit specific clinical behaviors, and improved responses to treatments, such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors, have been observed. Germline mutations in the BRCA 1/2 genes are the most well-known mechanisms of homologous recombination deficiency. However, other mechanisms, such as germline and somatic mutations in other homologous recombination genes and epigenetic modifications, have also been implicated in homologous recombination deficiency. The epidemiology and implications of these other mechanisms need to be better understood to improve the treatment strategies for these patients. Furthermore, an evaluation of various diagnostic tests to investigate homologous recombination deficiency is essential. Comprehension of the role of homologous recombination deficiency in ovarian cancer also allows the development of therapeutic combinations that can improve the efficacy of treatment. In this review, we discuss the epidemiology and management of homologous recombination deficiency in ovarian cancer patients.

Downloads

Download data is not yet available.

Downloads

Published

2019-02-14

Issue

Section

Review Articles

How to Cite

onadi, R. R. da C. C., Fogace, R. N., Miranda, V. C., & Diz, M. del P. E. (2019). Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics, 73(Suppl. 1), e450s. https://doi.org/10.6061/clinics/2018/e450s